Drug Trial Radar · NCT00388726
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
762
Actual
Start
Nov 2006
Primary completion
May 2009
Study completion Jun 2013
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Eisai Limited
- First posted
- Oct 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
E7389Drug
1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
Physician's ChoiceDrug
Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From date of randomization until death from any cause
Locations
137 sites in 17 countries. Site status is shown where the registry gives one.
US Oncology St. Vincent's Hospital - Bruno Cancer Center
Birmingham, Alabama
Bellflower Satellite
Bellflower, California
Research Center
Gilroy, California
US Oncology
Denver, Colorado
Florida Cancer Research Institute
Davie, Florida
Innovative Medical Research of South Florida, Inc.
Miami, Florida
Peachtree Hematology/Oncology Consultants, PC
Atlanta, Georgia
US Oncology
Niles, Illinois
US Oncology
Indianapolis, Indiana
University of Iowa Hospital and Clinic
Iowa City, Iowa
Hematology Oncology Clinic
Baton Rouge, Louisiana
Oncology Care Associates, P.L.L.C.
Saint Joseph, Michigan
US Oncology
Columbia, Missouri
Montana Cancer Specialists
Missoula, Montana
US Oncology
Las Vegas, Nevada
US Oncology
Albany, New York
North Shore Hematology/Oncology Associates
East Setauket, New York
Weill Cornell Breast Cancer Center
New York, New York
Carolina Hematology Oncology Associates
Charlotte, North Carolina
US Oncology
Raleigh, North Carolina
US Oncology
Eugene, Oregon
St. Vincent Medical Center
Portland, Oregon
US Oncology
Bedford, Texas
US Oncology
Dallas, Texas
US Oncology
Houston, Texas
US Oncology
McAllen, Texas
US Oncology
Midland, Texas
US Oncology
Tyler, Texas
US Oncology
Spokane, Washington
Northwest Medical Specialists
Tacoma, Washington
US Oncology
Vancouver, Washington
US Oncology
Yakima, Washington
Hosptial Interzonal General de Mar del Plata
Buenos Aires, Argentina
Clinica Universitaria Privada Reina Fabiola
Córdoba, Argentina
Sanatorio Frances
Córdoba, Argentina
Instituto de Oncologia y Especialidades Medicas
Rosario Santa Fe, Argentina
Clinica Especializada ISIS
Santa Fe, Argentina
Instituto Oncologico "Las Heras"
Bahía Blanca, Buenos Aires, Argentina
Hospital Britanico
C.a.b.a, Buenos Aires, Argentina
Instituto FIDES especialidades Medicas
La Plata, Buenos Aires, Argentina
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.